This is a randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimerâ€™s disease (AD). This trial will also assess the effects of MK-8931 on biomarkers related to AD pathology. Various biomarkers appear to reflect various aspects of AD biology. For example, brain volumetric measures assess brain tissue loss, presumably due to neuronal loss from the neurotoxic effects of amyloid. Therefore, volumetric measures that correlate with disease progression (including hippocampal, lateral ventricular, and total brain volumes) will be assessed using magnetic resonance imaging (MRI). All subjects will be required to have an MRI scan during screening in order to qualify for the trial and, subsequently, for safety monitoring. Subjects in the main cohort will have MRI scans after 13, 52 and 78 weeks of treatment or when clinically indicated.
This project was funded by: Merck
The term of this project was: April 2014 to April 2017
The number of subjects scanned during this project was: 10